Jon Morrow, PhD, MD

Jon Morrow, PhD, MD
Pathology, Anatomic Pathology, Hematopathology, Medical Renal Pathology and Electron Microscopy
Accepting new patients? Yes
Referrals required? MD to MD Consult
Patient type treated: Child; Adult
Board Certified in Anatomic Pathology

Jon S. Morrow, MD, PhD, is the Raymond Yesner Professor of Pathology, Professor of Molecular and Cellular Biology, the chair of Pathology and the Chief of Pathology at Yale New Haven Hospital. He has led Pathology for nearly 30 years. An internationally recognized physician-scientist, Dr. Morrow’s research has pioneered studies on the structure, function and genetics of complex cell membrane scaffolds. These studies were among the first to reveal the molecular basis of several hereditary disorders of blood cells, diseases most commonly afflicting young children, as well as the molecular basis of movement disorders such as hereditary ataxia. This work is reported in over 200 original research publications and reviews.

Under his leadership, the Pathology Department has grown to one of the nation’s foremost pathology programs, offering subspecialized expertise in all major areas of practice. Dr. Morrow personally co-authored the development of the first comprehensive anatomic pathology information system (CoPath®), now the most widely used anatomic lab information system across the Country. Building on that early initiative, the department was among the first to establish a dedicated informatics and computational pathology unit, and now leads the country in its information systems, which ensure optimal patient safety and laboratory efficiency. Other firsts for the Department under Dr. Morrow’s leadership include the introduction to Connecticut of computer-assisted cytologic screening and the incorporation of genetic sequencing technology, which is used for cancer diagnosis and tissue evaluation. Recent innovations include the development of new technologies that allow the identification of cancer patients who will optimally respond to emerging immunotherapies.